Compare OPEN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPEN | BEAM |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2020 | 2019 |
| Metric | OPEN | BEAM |
|---|---|---|
| Price | $2.00 | $24.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $4.27 | ★ $52.15 |
| AVG Volume (30 Days) | ★ 28.5M | 1.5M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,371,000,000.00 | $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $90.27 | $29.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $1.93 | $20.23 |
| 52 Week High | $9.44 | $38.26 |
| Indicator | OPEN | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 31.90 | 46.76 |
| Support Level | N/A | $24.30 |
| Resistance Level | $2.81 | $26.72 |
| Average True Range (ATR) | 0.16 | 1.30 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 15.45 | 33.33 |
Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital-light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.